These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21447724)

  • 21. Effectiveness of radiolabelled somatostatin analogues (
    Medina-Ornelas SS; García-Pérez FO
    Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
    Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First experience of durable cytoreduction in chronic lymphoid leukemia with
    Savovic T; Prior JO; Nicod-Lalonde M; Bressoud A; Roux S; Schaefer N; Meyer M
    Med Oncol; 2019 Mar; 36(5):41. PubMed ID: 30919094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.
    Kratochwil C; Mavriopoulou E; Rath D; Afshar-Oromieh A; Apostolopoulos D; Haufe S; Mier W; Haberkorn U; Giesel FL
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):116-20. PubMed ID: 24382404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors.
    Sandström M; Velikyan I; Garske-Román U; Sörensen J; Eriksson B; Granberg D; Lundqvist H; Sundin A; Lubberink M
    J Nucl Med; 2013 Oct; 54(10):1755-9. PubMed ID: 23929824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
    Acar E; Çapa Kaya G; Durak H
    Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
    Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S
    Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC.
    Cieciera M; Kratochwil C; Moltz J; Kauczor HU; Holland Letz T; Choyke P; Mier W; Haberkorn U; Giesel FL
    Diagn Interv Radiol; 2016; 22(3):201-6. PubMed ID: 27015320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 177Lu-Dotatate for midgut neuroendocrine tumours.
    Burki TK
    Lancet Oncol; 2017 Feb; 18(2):e74. PubMed ID: 28111117
    [No Abstract]   [Full Text] [Related]  

  • 34.
    Graham MM; Gu X; Ginader T; Breheny P; Sunderland JJ
    J Nucl Med; 2017 Sep; 58(9):1452-1458. PubMed ID: 28280220
    [No Abstract]   [Full Text] [Related]  

  • 35. Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.
    Nisa L; Savelli G; Giubbini R
    Ann Nucl Med; 2011 Feb; 25(2):75-85. PubMed ID: 21107762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.
    Malmberg C; Ripa RS; Johnbeck CB; Knigge U; Langer SW; Mortensen J; Oturai P; Loft A; Hag AM; Kjær A
    J Nucl Med; 2015 Dec; 56(12):1895-900. PubMed ID: 26429961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.
    Miederer M; Seidl S; Buck A; Scheidhauer K; Wester HJ; Schwaiger M; Perren A
    Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):48-52. PubMed ID: 18807033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery.
    Schmidt MC; Uhrhan K; Fischer T; Schmitz S; Markiefka B; Drzezga A; Stippel D
    Clin Nucl Med; 2015 Aug; 40(8):667-9. PubMed ID: 26053706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.